Kimelman & Baird’s Novo Nordisk NVO Stock Holding History

Kimelman & Baird’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$268K	Hold	10,000	–	–	0.04%	99
2017 Q3	$241K	Hold	10,000	–	–	0.04%	106
2017 Q2	$214K	Buy	+10,000	New	+$202K	0.03%	115

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Kimelman & Baird's NVO Position: Q4 2017 in Review

Kimelman & Baird held its Novo Nordisk (NVO) position steady in Q4 2017 at 10,000 shares worth $268K. The position accounts for 0.04% of the portfolio, ranked #99.

Kimelman & Baird first reported a position in NVO in Q2 2017 and has held it in 3 quarters since. 552 funds tracked by Wall St. Rank hold NVO as of Q4 2017.

Kimelman & Baird held 10,000 shares of Novo Nordisk worth $268K as of Q4 2017.
Kimelman & Baird left its Novo Nordisk share count unchanged in Q4 2017.
Novo Nordisk made up 0.04% of Kimelman & Baird's portfolio in Q4 2017, its #99 holding.
Kimelman & Baird first reported a position in Novo Nordisk in Q2 2017 and has held it in 3 quarters since.
552 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2017.

Based on Kimelman & Baird's 13F filing for Q4 2017, filed 6 Mar 2018.